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Abstract
Background
Successful antiretroviral therapy (ART) relies on the optimal level of ART adherence to
achieve reliable viral suppression, avert HIV drug resistance, and prevent avoidable deaths.
It has been shown that there are various groups of people living with HIV at high-risk of non-
adherence to ART in sub-Saharan Africa. The objective of this study was to examine the
cost effectiveness and value-of-information of directly administered antiretroviral therapy
(DAART) versus self-administered ART among people living with HIV, at high risk of non-
adherence to ART in sub-Saharan Africa.
Methods and findings
A Markov model was developed that describes the transition between HIV stages based on
the CD4 count, along with direct costs, quality of life and the mortality rate associated with
DAART in comparison with self-administered ART. Data used in the model were derived
from the published literature. A health system perspective was employed using a life-time
time horizon. Probabilistic sensitivity analysis was performed to determine the impact of
parameter uncertainty. Value of information analysis was also conducted. The expected
cost of self-administered ART and DAART were $5,200 and $15,500 and the expected
QALYs gained were 8.52 and 9.75 respectively, giving an incremental cost effectiveness
ratio of $8,400 per QALY gained. The analysis demonstrated that the annual cost DAART
needs to be priced below $200 per patient to be cost-effective. The probability that DAART
was cost-effective was 1% for a willingness to pay threshold of $5,096 for sub-Saharan
Africa. The value of information associated with the cost of DAART and its effectiveness
was substantial.
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Conclusions
From the perspective of the health care payer in sub-Saharan Africa, DAART cannot be
regarded as cost-effective based on current information. The value of information analysis
showed that further research will be worthwhile and potentially cost-effective in resolving the
uncertainty about whether or not to adopt DAART.
Introduction
The rate of infection with HIV/AIDS is very high among people living in sub-Saharan
African; since the start of the epidemic, there has been a rapid spread of this virus [1]. The
global population of people living with HIV in 2013 was approximately 35 million, with
approximately 70% residing in sub Saharan Africa [2]. There are approximately 24.7 mil-
lion HIV/AIDS infected individuals living in sub-Saharan Africa, with women making up
58% of this population [1]. Overall, 92% of the global population of HIV infected pregnant
women live in this region, and 90% of children infected with HIV globally reside in sub-
Saharan Africa [3]. Approximately 1.5 million newly infected HIV individuals were diag-
nosed in 2013 in sub Saharan Africa, with women, accounting for 25% of new HIV infec-
tions [2]. Over 1 million HIV/AIDS infected individuals die every year in Africa, and in
sub-Saharan Africa; in 2013 there were approximately 1.1 million deaths due to HIV/
AIDS [2].
Antiretroviral therapy (ART) is the main established standard treatment for people
infected with HIV, and has been shown to substantially improve the health status of infected
individuals [4–7]. Successful ART relies on the optimal level of ART adherence, to achieve a
reliable viral suppression, avert HIV drug resistance and prevent avoidable deaths [8–10].
However, adherence to ART has been a significant challenge for HIV infected individuals
on such treatment, and this is more severe among people who are classified as having a high
risk of non-adherence to medication, including prisoners, illicit drug users, and homeless
individuals [8, 10–12]. Various interventions have been adopted to improve medication
adherence among people living with HIV, such as education and counselling, patient
reminders, regimen simplifications and social support [5, 13] without definitive success.
Directly observed therapy has been successfully applied for supporting adherence among
tuberculosis patients where it has been shown to bring about health improvements, and is
an approach approved by the World Health Organization (WHO) [14]. Two systematic
reviews have examined the effectiveness of directly administered ART (DAART) versus
self-administered ART in improving virologic suppression of people living with HIV. How-
ever, the results of the two reviews are contradictory. While Ford et al, included only RCTs
and reported that “DAART seems to offer no benefit over self-administered ART”; Hart
et al included both RCTs and controlled trials and reported that “DAART had a significant
effect on virologic outcomes” [5, 15].
While the existing literature has focused on the effectiveness of DAART, to the best of our
knowledge, there have been no attempts to assess the likely cost-effectiveness of DAART inter-
ventions for promoting adherence to antiretroviral therapy amongst those at high-risk of non-
adhering from a sub-Saharan African perspective. Without objective information about the
current cost-effectiveness of DAART, it is difficult to plan substantial public health interven-
tions to improve ART adherence. Therefore, the objective of this study was to examine the
cost effectiveness DAART versus self-administered ART among people living with HIV, at
high risk of non-adherence to ART in sub-Saharan Africa.
Cost-effectiveness of directly administered antiretroviral therapy
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Methods
Model structure and assumptions
A model based cost-utility analysis was undertaken to evaluate the costs and benefits associated
with DAART in comparison with self-administered ART using a life time Markov model with
half cycle correction [16, 17]. The study patient population was HIV-positive infected adults in
sub-Saharan Africa, with a CD4 count> 500mm3, classified as being at high risk of non-
adherence to ART. Patients were assumed to be 20 years old (the impact of this assumption
was examined through sensitivity analysis) and the cycle length was one year. The perspective
of government health care payers in a sub-Saharan Africa setting was taken, with only direct
costs incurred by the health care provider being included in the model. The model structure
consists of five HIV health states, based on the clinical categories of patient CD4 cell counts
(Fig 1): State I, is HIV infected adults with a CD4 count of greater than 500 cells/mm3, without
any symptoms; State II is CD4 counts of greater than 350 cells/mm3 but less than or equal to
500mm3, and is categorised as mild asymptomatic; State III is CD4 counts greater than 200
Fig 1. Model structure of the different model states.
https://doi.org/10.1371/journal.pone.0191465.g001
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cells/mm3, but less than or equal to 350 cells/mm3, categorised as symptomatic; State IV is
CD4 counts less or equal to 200 cells/mm3, categorised as severe symptomatic /AIDS; and
State V is death. Patients can remain in the same state, or transition to any worse state or bet-
ter. This approach is supported by evidence which has demonstrated the possibility that
patients with AIDS can improve and move to a better HIV state, including the HIV asymp-
tomatic state [18]. Half cycle correction was applied to costs and benefits [16, 17]. Costs and
utilities were discounted at 3% [19, 20]. We used the WHO-CHOICE threshold of US$5,086
as the basis for assessments of cost-effectiveness [19, 20].
Model input parameters
Data used in the model were derived from the published literature and are summarised in
Table 1 and described below.
Table 1. Model input parameters.
Parameter Base case Range Reference
EFFECTIVENESS
Treatment effect of DAART compared to self-administered ART (relative risk) 1.29 1.12 to 1.48 [5]
COST
Annual HIV-related treatment costs (US$2014)
State I 176.44 383 to 639 [24, 28, 29]
State II 347.44 383 to 639 [24, 28, 29]
State III 498.44 404 to 674 [24, 28, 29]
State IV (AIDS) 1272.44 997 to 1661 [24, 28, 29]
Cost of DAART 964 723 to 1205 [30]
UTILITY
State I 0.94 0.92 to 1.00 [39]
State II 0.89 0.80 to 1.00 [24]
State III 0.83 0.45 to 1.00 [24]
State IV 0.73 0.24 to 0.80 [24]
TRANSITION PROBABILITIES
State I to State II 0.227 0.187 to 0.271 [21]
State I to State III 0.086 0.061 to 0.118 [21]
State I to State IV 0.062 0.040 to 0.090 [21]
State I to Death 0.022 0.010 to 0.042 [21]
State II to State I 0.195 0.163 to 0.230 [21]
State II to State III 0.202 0.170 to 0.238 [21]
State II to State IV 0.099 0.076 to 0.127 [21]
State II to Death 0.034 0.021 to 0.053 [21]
State III to State I 0.053 0.037 to 0.074 [21]
State III to State II 0.171 0.142 to 0.203 [21]
State III to State IV 0.237 0.204 to 0.273 [21]
State III to Death 0.043 0,028 to 0.063 [21]
State IV to State I 0.021 0.011 to 0.037 [21]
State IV to State II 0.095 0.072 to 0.122 [21]
State IV to State III 0.174 0.144 to 0.208 [21]
State IV to Death 0.106 0.082 to 0.134 [21]
Discount rate for costs and utilities (%) 3 0 to 5 [19, 20]
DAART: Directly administered ART
Annual HIV-related treatment cost per clinical state is sum of cost of ART, in-patient and out-patient treatment costs, laboratory tests and the treatment of
opportunitistic infections.
https://doi.org/10.1371/journal.pone.0191465.t001
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Transition probabilities
All the patients were assumed to start in ‘State I’ and thus have a CD4 count greater than 500
[21]. For HIV/AIDS disease progression under the self-administered ART arm, data were used
from patients that were followed-up between 2005 and 2009 from a referral hospital in Ethio-
pia (Table 1) [21]. The transition probabilities between health states in the directly adminis-
tered arm were based on an estimate of the treatment effect of DAART compared with self-
administered ART (relative risk) derived from a recent meta-analysis of 14 controlled trials
(both randomized and non-randomized) [5]. The effect of this relative risk (RR) was calculated
for each transition probability as follows [22]:
1. Increase the transition probability from one state to any better state:
DAART one state to any good state ¼ SAART x RR
2. Reduce the transition probability from one state to any worse state:
DAART one state to any worse state ¼ SAART x 1=RR:
Age-specific all-cause (not due to HIV/AIDS) mortality was applied to each state in the
model (Table 2), and was calculated using the age-specific mortality rate from sub-Saharan
Africa. This was applied in addition to the death rate from HIV/AIDS [23].
Utilities
All the utility values for each HIV/AIDS health were derived from a survey conducted in
South Africa using validated questionnaires, with HIV patients at different stages of HIV dis-
ease progression (Table 1) [24–27].
Costs
The costs in this analysis included treating opportunistic infections, and all the costs of inpa-
tient and outpatient health care utilization (Table 1) [24, 28–31]. The annual inpatient days
and outpatient visits were calculated based on annual mean inpatient days and outpatient visits
reported in the literature (Table 1)[32]. All the costs are converted to USA dollars, and inflated
to 2014 prices [33].
Table 2. ‘Natural’ age-specific mortality, South Africa 2015 projection.
Age (years) Probability of death
10 0.0021
15 0.0020
20 0.0034
25 0.0054
30 0.0087
35 0.0143
40 0.0177
45 0.0190
50 0.0220
55 0.0263
60 0.0320
65 0.0414
70 0.0591
75 0.0830
80 0.1138
https://doi.org/10.1371/journal.pone.0191465.t002
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Sensitivity analyses
A series of sensitivity analyses were carried out to examine the impact on the model results of
the uncertainty in the model input parameters. Structural uncertainty was assessed by assum-
ing that no reverse progression of HIV/AIDS patients was possible (i.e. from a bad state to a
better state). One way sensitivity analysis was performed, by increasing and decreasing all the
input parameters by 25%, in order to examine which parameters have the greatest influence on
the model results. Probabilistic sensitivity analysis (PSA) was performed with the model
parameters varied simultaneously according to pre-specified distributions. Dirichlet distribu-
tions were used for all transitions with more than 2 possible outcomes. Beta distributions were
used for all transitional probabilities with only two options, utilities and HIV state transition
probabilities. Gamma distributions were assigned to all costs and a lognormal distribution was
assigned to the effectiveness relative risk for DAART. 10,000 Monte Carlo simulations were
implemented with the results shown using a cost-effectiveness acceptability curve which pro-
vides a measure of the likelihood that a decision to apply a given intervention is cost effective
across a range of ‘willingness-to-pay’ thresholds, where the willingness-to-pay represents the
maximum amount decision makers are willing to pay for a unit of QALY gain.
Value of information analysis
The (individual patient) expected value of perfect information (EVPI) was calculated as the dif-
ference between the expected net health benefit (NHB) given full information and the expected
NHB given current information. The NHB measure is the increase in effectiveness multiplied
by the amount that the decision-maker is willing to pay per unit of increased effectiveness (i.e.
the cost-effectiveness threshold), minus the increase in cost. The population EVPI was esti-
mated by multiplying per patient EVPI by the effective population, i.e. the annual population
of at high-risk of non-adhering to ART discounted over the lifetime of the treatment (assumed
to be 50 years). Among people living with HIV in sub-Saharan Africa (24.4 million [1])
about 17.4% [34] were at high-risk of non-adhering to medication, and only 37% of people liv-
ing HIV in sub-Saharan were on ART in 2013 [1]. The effective population in sub-Saharan
Africa was therefore estimated at 1,600,000. The EVPI represents the maximum amount that a
decision-maker should be willing to pay for further information to guide the adoption decision
in the future, where additional research should be considered if the EVPI exceeds the cost of
research. The expected value of partial perfect information (EVPPI) was also calculated in
order to provide more focus for further research, by identifying the groups of inputs where it
would be valuable to have more accurate estimates. Specifically, EVPPI estimates were gener-
ated for the following sets of parameters: effectiveness, cost, utility, and probabilities. The
model used for the EVPPI was assumed to be linear for ease of computation.
Results
Base-case results
The base case results of the model are summarized in Table 3. The expected cost of self-
administered ART and DAART were $5,200 and $15,500 respectively and the QALYs gained
were 8.52 and 9.75 for self-administered ART and DAART respectively. The incremental cost
per QALY gained for DAART versus self-administered ART was $8,400 per QALY, this sug-
gests that DAART is not cost-effective based on the WHO-CHOICE threshold of US$5,086.
The results of the simplified model assuming no reverse disease progression yielded an ICER
of $9,700 per QALY.
Cost-effectiveness of directly administered antiretroviral therapy
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One-way sensitivity and threshold analyses
The results of the one-way sensitivity analysis are shown in Fig 2. The estimated ICER was
most sensitive to variations in the cost and effectiveness of DAART. When the annual cost of
DAART was varied from US$723 (best case scenario) to US$1,205 (worst case scenario) per
annum, the estimated ICER ranged from US$6,440per QALY gained to US$10,921. Similarly,
when the effectiveness of DAART was varied using the highest estimate from the literatre
(RR = 1.49, best case scenario) and the lowest (RR = 1.12, worst case scenario), the estimated
ICER was US$6,065.01 per QALY and US$17,987 per QALY respectively. The threshold
Table 3. Results of cost-utility analysis.
Intervention Cost (US$) Incremental cost (US$) QALYs Incremental QALYs ICER ((US$/QALY)
Base case

SAART 5,200 - 8.52. - -
DAART 15,500 10,300 9.75 1.23 8,400
Structural uncertainty
SAART 6,900 - 7.83 - -
DAART 17,600 10,700 8.94 1.11 9,700
ICER, incremental cost effectiveness ratio; PSA, Probability Sensitivity Analysis; QALY, Quality Adjusted Life Years (QALY)
Cost rounded to the nearest 100 dollars
base case with half-cycle correction
https://doi.org/10.1371/journal.pone.0191465.t003
Fig 2. Tornado plot for the results of the one-way sensitivity analysis.
https://doi.org/10.1371/journal.pone.0191465.g002
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analysis showed that as the annual cost of DAART increases, the cost of this treatment
becomes less and less cost-effective (Fig 3). For DAART to be cost-effective its annual cost
needs to be below US$500.
Probabilistic sensitivity analysis
The output for the probabilistic sensitivity analysis for 10,000 simulations is shown in Fig 4. All
of the model outputs were in the northeast quadrant of the cost-effectiveness plane, suggesting
that DAART is more costly and more effective than self-administered ART, it is never cost sav-
ing, and never has a negative impact on patient outcomes. At a threshold of US$9,000, DAART
was found to be 50% likely to be cost-effective, and if the willingness to pay for a QALY was US
$18,000 then DAART is likely to be at least 95% cost-effective. The probability that DAART was
cost-effective at the WHO-CHOICE threshold of US$5,086 was just 1% (Fig 5).
Value of information analysis
The population EVPI is illustrated in Fig 6. At cost-effectiveness threshold of $5,086, the popu-
lation EVPI becomes substantial (US$492 million), and is likely to exceed the cost of addi-
tional investigation. This suggests that further research will be potentially cost-effective. The
EVPI for each group of model parameters is illustrated in Fig 7 for a threshold for cost-effec-
tiveness of US$5,086. The value of information associated with research on the cost of DAART
and its effectiveness is US$1,706,707 and US$853,353 respectively. The other groups of model
inputs (see Table 1), such as transitional probabilities, QALYs gained and cost of treatment,
have no value of information associated with them. This suggests that if further research is
commissioned, it should focus on the relative effectiveness of DAART compared to self-
administered ART and its cost.
Fig 3. Threshold analysis for the annual cost of directly administered ART.
https://doi.org/10.1371/journal.pone.0191465.g003
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Discussion
Main findings
The cost-effectiveness of DAART versus self-administered ART was analysed using a model
based cost-utility analysis. The ICER of $8,700 per QALY gained indicates that when con-
sidering the WHO-CHOICE threshold of US$5,086, from the perspective of health care
payer in sub-Saharan Africa, directly administered ART cannot be regarded as cost-effec-
tive. The threshold analysis conducted for a range of costs for DAART, showed that for it to
be cost-effective, the annual cost of DAART needs to be priced below $500 per patient. The
results from the one-way sensitivity analysis indicate that the ICER is only sensitive to the
estimates of the effectiveness and annual cost of DAART. The value of information analysis
showed that further primary research will be worthwhile and potentially cost-effective in
resolving the uncertainty on whether or not to adopt DAART among HIV patients at high
risk of non-adherence. This should focus on establishing the relative effectiveness and cost
of DAART.
Comparison with other relevant economic evaluations
To the authors’ knowledge there are no comparative studies that have examined the cost-effec-
tiveness of DAART in a sub-Saharan Africa setting. This reflects a wider paucity of economic
evidence around HIV HIV treatment in low- and middle-income countries [35]. In a closely
related study that had a different patient population, McCabe and colleagues constructed a
Fig 4. Cost-effectiveness plane for the results of the probabilistic sensitivity analysis for 10,000 simulations. Note: Reference scenario is self-administered ART.
https://doi.org/10.1371/journal.pone.0191465.g004
Cost-effectiveness of directly administered antiretroviral therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0191465 January 23, 2018 9 / 15
mathematical model to examine the cost-effectiveness of DAART versus self-administered
ART among pregnant HIV-infected women in their third trimester in the US? [36]. Their
study found that the DAART was cost-effective from the perspective of health care payer in
the United States (ICER $14,233 per QALY) [36].
Strengths and limitations
We used a model based approach [37] which had several advantages [37, 38]. It allowed the
extrapolation of the outcomes reported in the literature to reflect long term consequences
and thus capture important economic outcomes. The effectiveness data were extracted
from a meta-analysis of multiple clinical trials instead of using data from just one clinical
trial [5]. Another important strength is that the cost data were taken from recent studies.
There are some limitations of this study that must be acknowledged. The main limitation
pertains to the inherent uncertainty in model input parameters and the observed sensitivity
of the ICER to certain key parameters. For example, some caution is required around the
estimates of the cost of DAART and self-administered ART as this may vary depending on
the particular health care systems in different countries. However, several sensitivity analy-
ses were conducted to assess both the model and structural uncertainties, including one-
way sensitivity analysis, threshold analysis and probabilistic sensitivity analysis. The ICER
results are robust over a range of model parameters and varying most of the parameters
Fig 5. Cost effectiveness acceptability curve (CEAC) for the probabilistic sensitivity analysis for 10,000 simulations across a range of willingness to pay values for
the QALY.
https://doi.org/10.1371/journal.pone.0191465.g005
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from worst-case to best-case scenarios did not significantly impact on the results. Another
important limitation is that the treatment effect estimate used for modelling DAART effec-
tiveness as based on a meta-analysis that included trials from heterogeneous contexts
Fig 6. Population Expected Value of Perfect Information (EVPI).
https://doi.org/10.1371/journal.pone.0191465.g006
Fig 7. Partial Expected Value of Perfect Information (EVPI).
https://doi.org/10.1371/journal.pone.0191465.g007
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(prison, methadone clinics), and only a minority of the included studies were conducted in
sub-Saharan Africa. Additionally, we used evidence from the Hart meta-analysis[5] that
included only randomised controlled trials which found no evidence of DAART effective-
ness over the Ford meta-analysis[15] that included both the randomised controlled trials
and non-randomised controlled trials.
In addition, the model adopted a simplistic representation, we did not consider the impact
of DAART on transmission of HIV in the target population. The main limiting assumption of
such approach includes the use of non-dynamic process at the level of the risk of each sexual
encounter, which could lead to a large underestimate of benefit. Similarly, the model could
underestimate cost effectiveness of DAART for prevention of HIV, because we assume no
direct benefit to the female partners. We focused only on DALYs averted.
Conclusions
The probability that DAART is cost-effective is zero if decision makers in the WHO Africa
region are willing to pay less than US$5,086 per QALY gained. As such, DAART is not cost-
effective based on the WHO suggested willingness to pay threshold for sub-Saharan Africa.
It was also found that DAART is not cost saving, and always has a positive impact on patient
outcomes compared to self-administered ART. For DAART to be cost-effective the annual
cost needs to be below US$500. The value of information associated with reducing the
uncertainty around the data influencing this decision is substantial, which suggests that fur-
ther research will be potentially cost-effective. Further research should therefore focus on
gaining further insights into the effectiveness and cost of DAART in a sub-Saharan Africa
setting.
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